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Small molecule approaches to regulation of gene
transcription
Regulation of gene expression is fundamental to the processes of cel-lular differentiation and organismal development. The human ge-
nome project has identified approximately 30,000 protein coding genes
in the genome and the regulation of expression of these genes in time
and space leads to the complex structure of the human form. How are
these genes expressed at the appropriate time and in the appropriate
place is a fundamentally important area of study which has yet to be
fully defined. Regulation of gene transcription is a primary means of
regulating gene expression. Transcription factors, both activators and
repressors, are the molecular arbiters regulating gene expression in or-
ganisms as diverse as bacteria, yeast and mammals. Aberrant gene tran-
scription plays a role in the onset of many diseases including cancer,
neurodegenerative disease and others. In eukaryotes at least, transcrip-
tional regulation involves a complex assembly of activators, repressors,
coactivators/corepressors, general transcription factors and RNA poly-
merases to elicit proper expression of protein coding, tRNA and rRNA
genes. In this review we focus on the regulation of protein coding genes
by RNA polymerase II and small molecule approaches to regulating
this complex process.
Transcriptional activators are a diverse set of molecules that activate
gene expression in response to environmental and developmental cues.
Activators generally bind to sequence elements upstream of protein
coding genes and thus confer specificity of gene expression. Transcrip-
tional activators are modular in nature containing discrete DNA bind-
ing domains and discrete activation domains (1). A wide variety of
DNA binding domains have been defined both functionally and struc-
turally and include domains such as the Zn-finger domain, the he-
lix-turn-helix domain among others (2). Activation domains are less
rigidly defined on the basis of structure and are generally sorted accord-
ing to the preponderance of amino acids found in the activation do-
main. Thus activation domains have been grouped as acidic(1), pro-
line-rich (3) and glutamine-rich (4).
Transcription factor modularity underlies current attempts at con-
structing artificial transcription factors (ATF) that will possess ratio-
nally designed activities. Domain swapping experiments used to define
the modularity of DNA binding and activation domains were the first
ATFs constructed and represent a proof of principle that such ap-
proaches were feasible. Thus far, rational design of ATFs has focussed
on molecules that mimic or enhance DNA binding specificities as well
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Triplex-forming oligonucleotides have been shown to
possess DNA binding activity (5). Triplex-forming
oligonucleotides fused to the VP16 activation domain
have been shown to activate transcription in cell culture
(6, 7). Peptide nucleic acids in which the phosphodiester
backbone normally found in nucleic acids is replaced
with amide bonds have also been used to bind DNA in a
designated manner (8). DNA binding modules have also
been designed based on the naturally occuring molecule
distamycin. DNA binding molecules based on this struc-
ture bind to the minor groove of DNA, are cell permeable
and have been shown to downregulate endogenous gene
expression (9). Dervan and colleagues have gone further
and designed a library of 27 molecules based on a hairpin
polyamine scaffold which are currently available for test-
ing in vivo (10). A related strategy has been to design zinc
finger domains using a genetic selection approach (11).
Designed zinc fingers when fused to the VP16 activation
domain have been shown to upregulate endogenous
erbB-2 and VEGF-A genes in cultured cell lines (12, 13).
Novel peptide activation domains were first identified
in a screen of randomized E.coli sequences fused to a
natural DNA binding domain (14). Randomized se-
quences containing hydrophobic sequences activated tran-
scription in yeast as strongly as natural activation do-
mains when fused to a natural DNA binding domain
(15). Amphipathic isoxazolidine was one of the first che-
mical mimics of an activation domain to be discovered
(16). Analogs of this structure have been synthesized and
shown to possess transcriptional activation capability (17).
A different approach involved identification of compounds
that bind to coactivators. Based on their ability to interact
with downstream proteins in the transcription complex
these compounds when fused to DNA binding domains
could presumably act as activator molecules in their own
right. Two compounds adamanolol and its derivative
wrenchnolol were identified as a micromolar ligand for
Sur-2 a subunit of the human Mediator complex (18, 19).
When fused to a DNA binding polyamide, the wrenchno-
lol conjugate could activate gene transcription in vitro
(20). This hybrid molecule was shown to recruit both
Sur2 and RNA polymerase II to the target DNA. Another
screen involving the identification of molecules that bind
the coactivator CBP/p300 led to the identification of two
peptide ligands that bind a key domain of CBP/p300.
When fused to a DNA binding domain these ligands
could activate transcription in cell culture at levels com-
parable to a natural activation domain (21). In a library
screen for compounds that bind the KIX domain of
CBP/p300, Kodadek et al. identified a peptoid com-
pound, KBP02, that binds the KIX domain in vitro and
is able to strongly activate transcription in a cell culture
based assay (22).
In addition RNA molecules have been found that
when fused to a DNA binding domain can also activate
transcription in yeast (23). While activation modules
have been identified in several molecular forms, the lev-
els of activation still do not approach those of natural ac-
tivation domains and this remains an outstanding design
problem. Transcriptional activation domains interact with
a variety of factors to elicit regulation of gene expression.
Knowledge of these key biochemical interactions has
also been used to identify compounds that perturb these
interactions and thus regulate gene expression. One of
the most studied activation domain interactions is that of
the p53 activation domain with MDM2. p53 is a trans-
criptional activator and tumor suppressor protein whose
normal function is to activate genes involved in cell-cycle
arrest, apoptosis and DNA repair (24, 25). MDM2 inter-
acts with the p53 activation domain thereby blocking its
transcriptional activation function. Screening and design
based strategies have been used to identify a number of
molecules that can inhibit the p53-MDM2 interaction
(26). One of the first compounds to be identified that in-
hibits the p53-MDM2 interaction was nutlin. This mole-
cule binds to MDM2 and can inhibit cancer cell growth
and kill tumors in a mouse xenograft model after oral ad-
ministration. Benzodiazepinone was also shown to be a
human MDM2 (HDM2) antagonist (27). A distinct class
of inhibitor was identified that interacts with p53 as op-
posed to MDM2. Bisthiophenylfuran 13 (RITA) was
identified through a library screen and was shown to
completely stop tumor growth in a mouse xenograft mo-
del system (28).
The histone acetyltransferase CBP/p300 is another
coactivator that binds to many transcription factors to re-
organize chromatin and activate transcription. CBP/p300
has several interaction domains that are able to interact
with diverse transcription factors and each of these do-
mains is a prime target for the discovery of molecules that
inhibit transcription factor interaction. One of the tran-
scription factors that target CBP/p300 is HIF-1alpha, the
hypoxia responsive transcription factor. A fungal metab-
olite, chetomin, was isolated in a high throughput screen
for inhibitors of the HIF-1alpha-p300 interaction (29).
Chetomin inhibits the HIF-1alpha-p300 interaction in
vitro as well as inhibiting hypoxia induced transcription
in vivo by 50% (29). Because p300 binds many transcrip-
tion factors, chetomin was also screed for inhibition of
transcription by other transcriptional activators and it
was shown that STAT2 activation was also inhibited by
chetomin (29) indicating that specificity remains an is-
sue in the design of CBP/p300 inhibitors. Using a NMR
based screening approach for compounds that inhibit the
transcriptional activator CREB and its interaction with
CBP, Montminy et al. identified a molecule designated
KG-501 as an inhibitor of this protein-protein interac-
tion (30). In cell culture studies, KG-501 inhibited tran-
scription of CREB dependent genes via its direct inhibi-
tion of the CREB-CBP interaction. Specificity was again
shown to be an issue as KG-501 also inhibits CBP inter-
action with the transcriptional activator NF-kB.
In yet a further refinement of the construction of arti-
ficial transcription factors, several groups have developed
ATFs whose activity is ligand dependent thereby intro-
ducing the capability of regulating the activation func-
tion of these factors in a controlled manner. In the first
example, Bujard et al. developed a doxycyclin inducible
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system for regulating transcriptional activation (31). In a
second, Schreiber et al. developed chemical inducers of
transcription factor dimerization to regulate transcrip-
tion factor activity (32). In yet another example, an
allosteric ligand-responsive ATF was designed such that
a zinc finger DNA binding domain was linked to the
VP16 activation domain via the ligand binding domain
of a steroid receptor. This fusion was responsive to ste-
roid hormone and showed that regulatable transcription
factors could be constructed from existing ligand binding
domains (33).
The advent of whole genome expression profiling has
added a new dimension to the search for small molecules
that activate defined transcriptional pathways. Uretup-
amine was identified in a screen for small molecules that
bind the yeast protein Ure2p (34). Subsequent compari-
son of the whole genome transcription profile of uretup-
amine treated cells with that of ure2 cells showed that
uretupamine affects only a subset of genes affected by
ure2 mutation, suggesting a previously unexpected level
of specificity of the uretupamine molecule. In a similar
manner splitomycin was isolated as a small molecule in-
hibitor of the yeast histone deacetylase Sir2p and cells
treated with splitomycin exhibited a transcriptional pro-
file similar to that of sir2 deleted cells (35). Furthermore,
the splitomycin gene expression profile also resembled to
a lesser extent the profile of a hst1 deletion strain suggest-
ing that splitomycin might inhibit not only Sir2 but an
additional histone deacetylase Hst1. Derivatives of spli-
tomycin were subsequently developed that showed selec-
tivity towards either Sir2 or Hst1 and subsequently it was
shown that this selectivity could be corroborated by com-
paring the gene expression profiles of the derivatives with
those of either sir2 or hst1 mutant cells (36). Whole ge-
nome expression profiling holds great promise for the
identification of small molecules with specific gene ex-
pression targeting. By comparing the transcriptional pro-
files of new compounds with those of known therapeutic
classes, predictions of a new compound’s potential thera-
peutic use and efficacy can be inferred. At present, the
expense of microarray technology prohibits use of this
technology as a standard screening tool, however an al-
ternative that has been shown effective is the use of only a
few marker genes from a complete profile as a sort of
mini-array with which to look for compounds that can
induce the mini-array. Stegmaier et al. used this ap-
proach to identify compounds that induce terminal dif-
ferentiation of acute myelogenous leukemias cells (37).
Compounds that were identified on the basis of their
ability to induce a set of marker genes were subsequently
shown to also induce the whole genome profile associ-
ated with differentiation. Clearly, if a set of marker genes
can be inferred from a whole genome transcriptional
profile this approach should be applicable to a more effi-
cient screening for new compounds that affect a given
transcriptional profile.
Small molecule approaches to the design of synthetic
transcription factors as well as identification of com-
pounds that operate through defined transcriptional tar-
geting represent a promising avenue of research for the
future. In this review we have highlighted a few exam-
ples which typify the approaches used thus far to isolate a
variety of molecules that directly act on transcription fac-
tors and the assembly of a functional transcription com-
plex at the promoters of protein coding genes. While initial
progress in the design of synthetic activator molecules is
promising thus far these molecules still lack many char-
acteristics of natural activator molecules. Synthetic acti-
vators still do not approach the levels of transcriptional
activation observed with natural activators, and as well
do not show cell or tissue specificity. In addition cell per-
meability remains an issue for both synthetic activator
molecules and small compound regulators. Clearly a
convergence of chemical and biological information will
be required to advance the field to a point where these
approaches will ultimately give rise to new therapeutic
agents.
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